Au Yeung, K. H. R., Russell, V., Choi, W., Wong, A., Tsui, L., Lee, Y. Y. C., Li, J., Gill, H., Ip, H.-W., Kwong, Y. L., Dave, T., Ondrejka, S. L., Bhagat, G., Chadburn, A., Rutherford, S. C., Koff, J. L., Jaye, D. L., Czader, M., Louissaint, A., … Tse, E. (2021). ALK-Negative Anaplastic Large Cell Lymphomas Encompass Distinct Subgroups Including an ALK-Positive-like Subgroup with Favorable Prognosis. Blood, 138(Supplement 1), 2403–2403. https://doi.org/10.1182/blood-2021-148807

Koffman, Dr. B., Stewart, C., Avruch, L., Bailey, N., Brumble, R., Byrd, J. C., Danilov, A. V., Davids, M. S., Furman, R., Jain, N., Kay, N. E., Lamanna, N., Mato, A. R., Skarbnik, A., Ujjani, C. S., & Pagel, J. M. (2021). Awareness, Knowledge, and Preferences of United States (US) Patients with Chronic Lymphocytic Leukemia (CLL) and Their Caregivers Related to Finite Duration (FD) Therapy and Minimal (Measurable) Residual Disease (MRD). Blood, 138(Supplement 1), 1927–1927. https://doi.org/10.1182/blood-2021-145046

Sarkaria, S. M., Bao, S., Zhang, C., & Ding, L. (2021). Comprehensive Cellular Dissection of the Bone Marrow Microenvironment in Primary Myelofibrosis. Blood, 138(Supplement 1), 200–200. https://doi.org/10.1182/blood-2021-153727

Ricker, E. C., Ryu, Y. K., & Amengual, J. E. (2021). Daratumumab Plus Chemotherapy Induces Complete Responses in a Consecutive Series of Four Patients with Plasmablastic Lymphoma. Blood, 138(Supplement 1), 4573–4573. https://doi.org/10.1182/blood-2021-150800

Albitar, M., Zhang, H., Goy, A. H., Xu-Monette, Z., Bhagat, G., Visco, C., Tzankov, A., Fang, X., Zhu, F., Dybkaer, K., Chiu, A., Tam, W., Zu, Y., Hsi, E. D., Hagemeister, F. B., Huh, J., Ponzoni, M., Ferreri, A. J. M., Moller, M., … Young, K. H. (2021). Determining Clinical Course of Diffuse Large B-Cell Lymphoma Using Targeted Transcriptome and Machine Learning Algorithms. Blood, 138(Supplement 1), 2395–2395. https://doi.org/10.1182/blood-2021-148841

Ricker, E. C., Estrella, B., Pazos, M. A., & Amengual, J. E. (2021). Dual Targeting of EZH2 and HDAC with Tazemetostat and Belinostat Promotes Immunogenicity in GC-DLBCL. Blood, 138(Supplement 1), 2410–2410. https://doi.org/10.1182/blood-2021-153460

Zonder, J. A., Richter, J., Bumma, N., Brayer, J., Hoffman, J. E., Bensinger, W. I., Wu, K. L., Xu, L., Chokshi, D., Boyapati, A., Sharma, M., Rodriguez Lorenc, K., Kroog, G. S., Dhodapkar, M. V., Lentzsch, S., Cooper, D., & Jagannath, S. (2021). Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 138(Supplement 1), 160–160. https://doi.org/10.1182/blood-2021-144921

Bahlis, N. J., Richard, S., White, D. J., Grosicki, S., Chen, C., Delimpasi, S., Sutherland, H. J., Maslyak, Z., Sebag, M., Gavriatopoulou, M., Lentzsch, S., Chari, A., Simonova, M., Spicka, I., Kriachok, I., Dimopoulos, M. A., Pylypenko, H., Auner, H. W., Leleu, X., … Richardson, P. G. (2021). Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd). Blood, 138(Supplement 1), 1634–1634. https://doi.org/10.1182/blood-2021-146324

Lentzsch, S., Lipe, B., Tuchman, S. A., Bahlis, N. J., Bensinger, W. I., Sebag, M., Sutherland, H. J., Monge, J., Gasparetto, C. J., Baljevic, M., Callander, N. S., Venner, C. P., White, D. J., Kotb, R., Chen, C. I., Schiller, G. J., Madan, S., Leblanc, R., DeCastro, A., … Biran, N. (2021). Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb). Blood, 138(Supplement 1), 1651–1651. https://doi.org/10.1182/blood-2021-150232

Tremblay, D., Srisuwananukorn, A., Ronner, L., Podoltsev, N., Gotlib, J., Heaney, M. L., Kuykendall, A. T., O’Connell, C. L., Shammo, J. M., Fleischman, A., Mesa, R. A., Yacoub, A., Hoffman, R., Moshier, E., Zubizarreta, N., & Mascarenhas, J. (2021). European Leukemianet (ELN) Response Predicts Disease Progression but Not Thrombosis or Death in Polycythemia Vera (PV): An Analysis of a Multicenter Database. Blood, 138(Supplement 1), 240–240. https://doi.org/10.1182/blood-2021-148020

Youn, M., Smith, S. M., Lee, A. G., Chae, H.-D., Spiteri, E., Erdmann, J., Galperin, I., Murphy, L. C., Donato, M., Abidi, P., Bittencourt, H., Lacayo, N. J., Dahl, G., Aftandilian, C., Davis, K. L., Matthews, J. A., Kornblau, S. M., Huang, M., Sumarsono, N., … Sakamoto, K. M. (2021). Gene Expression Analysis of CML Patients across the Age Spectrum. Blood, 138(Supplement 1), 1473–1473. https://doi.org/10.1182/blood-2021-148701

Leeman-Neill, R. J., Thakkar, D., Ondrejka, S. L., Hsi, E. D., Chadburn, A., Mejia Saldarriaga, M., Rutherford, S. C., McCall, C. M., Aljurf, T., McKinney, M., Koff, J. L., Jaye, D. L., Cohen, J. B., Soliman, D. S., Louissaint, A., Ong, C. K., Cheng, C. L., Lee, L., Behdad, A., … Bhagat, G. (2021). Genomic and Transcriptional Characterization of Primary Mediastinal Large B Cell Lymphoma. Blood, 138(Supplement 1), 2398–2398. https://doi.org/10.1182/blood-2021-149745

Muchtar, E., Dispenzieri, A., Wisniowski, B., Palladini, G., Milani, P., Merlini, G., Schönland, S., Veelken, K., Hegenbart, U., Kumar, S., Kastritis, E., Dimopoulos, M. A., Liedtke, M., Witteles, R., Sanchorawala, V., Szalat, R., Landau, H. J., Petrlik, E., Lentzsch, S., … Gertz, M. A. (2021). Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival. Blood, 138(Supplement 1), 2720–2720. https://doi.org/10.1182/blood-2021-149222

Muchtar, E., Wisniowski, B., Palladini, G., Milani, P., Merlini, G., Schönland, S., Veelken, K., Hegenbart, U., Dispenzieri, A., Kumar, S., Leung, N., Kastritis, E., Dimopoulos, M. A., Liedtke, M., Witteles, R., Sanchorawala, V., Szalat, R., Landau, H. J., Petrlik, E., … Gertz, M. A. (2021). Graded Renal Response Criteria for Light Chain (AL) Amyloidosis. Blood, 138(Supplement 1), 2721–2721. https://doi.org/10.1182/blood-2021-149594

Lipsky, A. H., Hill, B. T., Winter, A. M., Jurcic, J. G., Heaney, M. L., Rosenblat, T. L., Chiaramonte, M., Weissbrot, H., & Lamanna, N. (2021). High Rates of Undetectable Minimal Residual Disease Remissions with Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL). Blood, 138(Supplement 1), 1555–1555. https://doi.org/10.1182/blood-2021-150914

Estrella, B., Liu, Y., Ricker, E. C., Pazos, M. A., Fiorito, J., Zuccarello, E., Calcagno, E., Honig, B., Arancio, O., & Amengual, J. E. (2021). Histone Acetyltransferase (HAT) Activator, YF2, Modulates the p53:BCL6 Axis and Antigen Presentation in Diffuse Large B-Cell Lymphomas. Blood, 138(Supplement 1), 2254–2254. https://doi.org/10.1182/blood-2021-151442

Paolino, J. D., Flamand, Y., Stevenson, K. E., Koch, V., Athale, U. H., Cole, P. D., Gennarini, L. M., Kahn, J. M., Kelly, K. M., Laverdiere, C., Leclerc, J.-M., Michon, B., Place, A. E., Supko, J. G., Tran, T. H., Welch, J. J. G., Neuberg, D. S., Sallan, S. E., Silverman, L. B., & Vrooman, L. M. (2021). Impact of Age, Body Surface Area, and Body Mass Index on Pegaspargase Toxicity and Pharmacokinetics: A Report from the DFCI ALL Consortium. Blood, 138(Supplement 1), 3396–3396. https://doi.org/10.1182/blood-2021-151313

Park, J. H., Nikiforow, S., Kim, S., Hu, Z.-H., Moskop, A., Ahmed, S., Bilal Abid, M., Badar, T., Bredeson, C., Brown, V., Cairo, M. S., Díaz, M., Dholaria, B., Ganguly, S., Grover, N. S., Hanna, R., Hematti, P., Kohorst, M. A., Lazarus, H., … Perales, M.-A. (2021). Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL). Blood, 138(Supplement 1), 3880–3880. https://doi.org/10.1182/blood-2021-148652

Hopson, M., Bhutani, D., Sarkaria, S. M., Maurer, M., Griffin, J., Lentzsch, S., & Chakraborty, R. (2021). Impact of Light Chain Isotype on Clinical Features and Outcomes in Systemic AL Amyloidosis. Blood, 138(Supplement 1), 4726–4726. https://doi.org/10.1182/blood-2021-149299

Hill, B. T., Roth, C. J., Kositsky, R., Dave, T., Love, C., McKinney, M., Galal, A., Neff, J. L., Mian, A., Kendall, E., Ondrejka, S. L., Chiaramonte, M., Bhagat, G., Ofori, K., Reshef, R., Kovach, A. E., Sethi, T., Mason, E. F., Bhaskar, S., … Dave, S. S. (2021). Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy. Blood, 138(Supplement 1), 165–165. https://doi.org/10.1182/blood-2021-145764

Pemmaraju, N., Kantarjian, H., Sweet, K., Wang, E. S., Lane, A. A., Ali, H., Stein, A. S., Yacoub, A., Rizzieri, D. A., Vasu, S., Gupta, V., Lee, S., Schiller, G. J., Foran, J. M., Taparia, M. S., Rosenblat, T. L., Walter, R. B., Sieminski, D., Anant, M., … Konopleva, M. (2021). Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies. Blood, 138(Supplement 1), 2318–2318. https://doi.org/10.1182/blood-2021-145344

Batlevi, C. L., Park, S. I., Nastoupil, L., Phillips, T., Amengual, J. E., Andorsky, D., Campbell, P., McKay, P., Pagel, J. M., Leonard, J. P., Yang, J., O’Connor, H., Hamlett, A., Adib, D., & Morschhauser, F. (2021). Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma. Blood, 138(Supplement 1), 2207–2207. https://doi.org/10.1182/blood-2021-148199

Kahn, J. M., Bo-Subait, S., Buchbinder, D. K., Hamilton, B. K., Schoemans, H., Brazauskas, R., Phelan, R., & Satwani, P. (2021). Late Effects after Allogeneic Hematopoietic Cell Transplantation Among Children and Adolescents with Non-Malignant Disorders: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR). Blood, 138(Supplement 1), 412–412. https://doi.org/10.1182/blood-2021-151446

Neelapu, S. S., Chavez, J. C., Sehgal, A. R., Epperla, N., Ulrickson, M. L., Bachy, E., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., Reshef, R., Leslie, L. A., Oluwole, O. O., Yakoub-Agha, I., Khanal, R., Rosenblatt, J. D., Sherman, M., Dong, J., Giovanetti, A., … Jacobson, C. (2021). Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). Blood, 138(Supplement 1), 93–93. https://doi.org/10.1182/blood-2021-148473

Li, S., Fu, J., Yang, J., Ma, H., Mapara, M. Y., Marcireau, C., & Lentzsch, S. (2021). MAP4K2 Silencing Overcomes IMiDs-Resistance in Multiple Myeloma. Blood, 138(Supplement 1), 2662–2662. https://doi.org/10.1182/blood-2021-151844

Veludhandi, A., John, T. D., Bakshi, N., Arnold, S. D., Bhatia, M., Lane, P. A., Meacham, L., Khemani, K., Chaudhury, S., Olowoselu, F. O., Kasow, K. A., Hsieh, M., Abraham, A., Guilcher, G. M. T., & Krishnamurti, L. (2021). Mobility and Muscle Strength in Recipients of Hematopoietic Cell Transplantation for Sickle Cell Disease: A Preliminary Report from Sickle Transplant Evaluation of Longterm and Late Effects Registry (STELLaR). Blood, 138(Supplement 1), 3030–3030. https://doi.org/10.1182/blood-2021-152383

De Botton, S., Yee, K., Recher, C., Wei, A. H., Montesinos, P., Taussig, D., Pigneux, A., Braun, T., Curti, A., Esteve, J., Grove, C., Jonas, B. A., Khwaja, A., Legrand, O., Peterlin, P., Arnan Sangerman, M., Blum, W. G., Cilloni, D., Hiwase, D., … Fenaux, P. (2021). Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Blood, 138(Supplement 1), 2351–2351. https://doi.org/10.1182/blood-2021-144912

Garcia, J. S., Wei, A. H., Jacoby, M. A., Fong, C. Y., Borate, U., Baer, M. R., Cunningham, I., Odenike, O., Jurcic, J. G., Nowak, D., Peterlin, P., Platzbecker, U., Dunshee, D., Zhou, Y., Hoffman, D., Sun, Y., Popovic, R., Ainsworth, B., Naqvi, K., … Garcia-Manero, G. (2021). Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine. Blood, 138(Supplement 1), 241–241. https://doi.org/10.1182/blood-2021-145613

Prockop, S., Mahadeo, K. M., Beitinjaneh, A., Choquet, S., Stiff, P., Reshef, R., Satyanarayana, G., Dahiya, S., Parmar, H., Ye, W., Gamelin, L., & Dinavahi, R. (2021). Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE). Blood, 138(Supplement 1), 301–301. https://doi.org/10.1182/blood-2021-147274

Askew, M., Smaldone, A., Gold, M. A., Smith-Whitley, K., Strouse, J. J., Jin, Z., & Green, N. S. (2021). National Survey of Pediatric Sickle Cell Providers on Their Contraceptive Practices for Female Patients. Blood, 138(Supplement 1), 1898–1898. https://doi.org/10.1182/blood-2021-154083

Gru, A. A., Snowden, C., Williams, E., Barrionuevo, C., Sanches, J., Battistella, M., Mo, S., Pulitzer, M., Bhagat, G., Servitje, O., Miyashiro, D., Climent, F., Dueñas, D., Casavilca, S., Guyton-Ringbloom, Ki., Beltran, B. E., Castro, D., Toomey, N. L., Barreto, L., … Ramos, J. C. (2021). Notable Patterns in the Genomic Landscape of Adult T-Cell Leukemia/Lymphoma Encountered in HTLV-1 Endemic Western World Regions. Blood, 138(Supplement 1), 810–810. https://doi.org/10.1182/blood-2021-154275

Srisuwananukorn, A., Percha, B., Abu-Zeinah, G., Scandura, J., Krichevsky, S., Taylor, E., Silver, R. T., Thibaud, S., Ronner, L., Podoltsev, N., Gotlib, J., Heaney, M. L., Kuykendall, A. T., O’Connell, C., Shammo, J. M., Fleischman, A., Mesa, R. A., Yacoub, A., Hoffman, R., … Tremblay, D. (2021). Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics. Blood, 138(Supplement 1), 2583–2583. https://doi.org/10.1182/blood-2021-150561

Santini, V., Fenaux, P., Van Eygen, K., Raza, A., Germing, U., Font, P., Diez-Campelo, M., Thepot, S., Vellenga, E., Patnaik, M. M., Jang, J. H., Sherman, L., Berry, T., Feller, F., Dougherty, S., Sun, L., Wan, Y., Rizo, A., Huang, F., & Platzbecker, U. (2021). On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs). Blood, 138(Supplement 1), 2598–2598. https://doi.org/10.1182/blood-2021-148876

Afify, Z., Orjuela, M., Smith, C. M., Dalal, M., Ford, J. B., Pillai, P., Robles, J., Reddy, S., McCormack, S., Ehrhardt, M. J., Ureda, T., Edington, H., Miller, T. P., Rubinstein, J., Marks, L., & Mason, C. C. (2021). Outcome of Post Solid Organ Transplant Burkitt Lymphoma (PSOT-BL): A Report from the Pediatric PTLD Collaborative (PPC). Blood, 138(Supplement 1), 2498–2498. https://doi.org/10.1182/blood-2021-149033

Chakraborty, R., Rybicki, L. A., Preussler, J. M., Devine, S., Baker, K. S., Syrjala, K., Yi, J. C., Whitten, J. L., Shaw, B. E., & Majhail, N. S. (2021). Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: Secondary Analysis of Two Randomized Controlled Trials on Survivorship Care Plans. Blood, 138(Supplement 1), 431–431. https://doi.org/10.1182/blood-2021-149281

Paolino, J. D., Harris, M. H., Stevenson, K. E., Koch, V., Cole, P. D., Gennarini, L. M., Kahn, J. M., Kelly, K. M., Kirsch, Ii., Michon, B., Place, A. E., Tran, T. H., Welch, J. J. G., & Silverman, L. B. (2021). Performance of Next Generation Sequencing for Minimal Residual Disease Detection for Pediatric Patients with Acute Lymphoblastic Leukemia: Results from the Prospective Clinical Trial DFCI 16-001. Blood, 138(Supplement 1), 3485–3485. https://doi.org/10.1182/blood-2021-152369

Lee, H. J., Choi, M., Siddiqi, T., Barrientos, J., Wierda, W. G., Isufi, I., Tuscano, J., Lamanna, N., Subbiah, S., Koff, J. L., Leslie, L. A., Goldenberg, A., Chung, G. G., Breitmeyer, J. B., Yazji, S., Wang, Y., Wang, M., Jamieson, C., & Kipps, T. J. (2021). Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL). Blood, 138(Supplement 1), 3534–3534. https://doi.org/10.1182/blood-2021-148779

Mato, A. R., Pagel, J. M., Coombs, C. C., Shah, N. N., Lamanna, N., Munir, T., Lech-Marańda, E., Eyre, T. A., Woyach, J. A., Wierda, W. G., Cheah, C. Y., Cohen, J. B., Roeker, L. E., Patel, M. R., Fakhri, B., Barve, M. A., Tam, C. S., Lewis, D. J., Gerson, J. N., … Jurczak, W. (2021). Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study. Blood, 138(Supplement 1), 391–391. https://doi.org/10.1182/blood-2021-147599

Wang, M., Shah, N. N., Alencar, A. J., Gerson, J. N., Patel, M. R., Fakhri, B., Jurczak, W., Tan, X. N., Lewis, K., Fenske, T. S., Coombs, C. C., Flinn, I. W., Lewis, D. J., Le Gouill, S., Palomba, M. L., Woyach, J. A., Pagel, J. M., Lamanna, N., Cohen, J. B., … Cheah, C. Y. (2021). Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study. Blood, 138(Supplement 1), 381–381. https://doi.org/10.1182/blood-2021-149138

Tisdale, J. F., Thompson, A. A., Mapara, M. Y., Kwiatkowski, J. L., Krishnamurti, L., Aygun, B., Kasow, K. A., Rifkin-Zenenberg, S., Schmidt, M., Pierciey, F. J., Whitney, D., Rogers, C., Nnamani, M., Foos, M., Miller, A., Zhang, X., Lynch, J., Walters, M. C., Kanter, J., & Bonner, M. (2021). Polyclonality Strongly Correlates with Biological Outcomes and Is Significantly Increased Following Improvements to the Phase 1/2 HGB-206 Protocol and Manufacturing of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy (GT). Blood, 138(Supplement 1), 561–561. https://doi.org/10.1182/blood-2021-147760

Gladstone, D. E., Howard, C., Lyu, M.-A., Mock, J., Adams, D., Gibbs, K., Li, L., Huang, M., Zeng, K., D’Alessio, F., Herlihy, J., Trevino, S., Hari, P., Sadeghi, T., Parmar, S., Slutsky, A., & Mukherjee, S. (2021). Randomized, Multi-Center, Double-Blinded, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) in the Treatment of COVID-19 Induced ARDS. (RESOLVE Trial). Blood, 138(Supplement 1), 828–828. https://doi.org/10.1182/blood-2021-153616

Scuoppo, C., Cai, B., Ofori, K., Scholze, H., Basso, K., Pasqualucci, L., & Dalla-Favera, R. (2021). Repurposing NAD Salvage Inhibitors for GCB Diffuse Large-B Cell Lymphoma. Blood, 138(Supplement 1), 789–789. https://doi.org/10.1182/blood-2021-151079

Baljevic, M., Gasparetto, C., Schiller, G. J., Tuchman, S. A., Callander, N. S., Lentzsch, S., Monge, J., Kotb, R., Bahlis, N. J., White, D., Chen, C. I., Sutherland, H. J., Madan, S., Leblanc, R., Sebag, M., Venner, C. P., Bensinger, W. I., Biran, N., DeCastro, A., … Lipe, B. (2021). Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment. Blood, 138(Supplement 1), 2751–2751. https://doi.org/10.1182/blood-2021-150998

Walters, M. C., Tisdale, J. F., Mapara, M. Y., Krishnamurti, L., Kwiatkowski, J. L., Aygun, B., Kasow, K. A., Rifkin-Zenenberg, S., Jaroscak, J., Garbinsky, D., Chirila, C., Gallagher, M. E., Zhang, X., Ho, P.-R., Thompson, A. A., & Kanter, J. (2021). Sustained Improvements in Patient-Reported Quality of Life up to 24 Months Post-Treatment with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy. Blood, 138(Supplement 1), 7–7. https://doi.org/10.1182/blood-2021-146905

Love, C., Pillai, R., Ondrejka, S. L., Bhagat, G., Chadburn, A., McKinney, M., Koff, J. L., Soliman, D. S., Czader, M., Louissaint, A., Li, S., Ong, C. K., Behdad, A., Evens, A. M., Natkunam, Y., Norgaard, P. H., Leppa, S., Tse, E., Chapman, J. R., … Dave, S. (2021). The Atlas of Blood Cancer Genomes (ABCG) Project: A Comprehensive Molecular Characterization of Leukemias and Lymphomas. Blood, 138(Supplement 1), 2213–2213. https://doi.org/10.1182/blood-2021-151346

Pemmaraju, N., Cuglievan, B., Lasky, J. L., Kheradpour, A., Hijiya, N., Stein, A. S., & Pawlowska, A. B. (2021). Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in Pediatric Patients with Tagraxofusp, a CD123-Targeted Therapy. Blood, 138(Supplement 1), 2317–2317. https://doi.org/10.1182/blood-2021-150393

Hijiya, N., Kapoor, S., Descamps, L., Bayar, M. A., & Ramscar, N. (2021). Trial in Progress: A Multicenter, Open-Label, Phase Ib/II Study to Determine the Dose and Safety of Asciminib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated with ≥1 Prior Tyrosine Kinase Inhibitor. Blood, 138(Supplement 1), 2561–2561. https://doi.org/10.1182/blood-2021-151198

Horwitz, S. M., Foran, J. M., Maris, M., Lue, J. K., Sawas, A., Okada, C., Feldman, T. A., Sokol, L., Mei, M., Flinn, I. W., Villa, D., Percival, M.-E. M., Jagadeesh, D., Savage, K. J., Akilov, O., Diefenbach, C. S., Kim, Y. H., Lin, G. H. Y., Catalano, T., … Ansell, S. M. (2021). Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies. Blood, 138(Supplement 1), 2448–2448. https://doi.org/10.1182/blood-2021-154490

Roeker, L. E., Eyre, T. A., Thompson, M. C., Lamanna, N., Coltoff, A. R., Davids, M. S., Baker, P. O., Leslie, L., Rogers, K. A., Allan, J. N., Cordoba, R., Lopez-Garcia, A., Antic, D., Pagel, J. M., Martinez-Calle, N., García-Marco, J. A., Hernández-Rivas, J.-Á., Miras, F., Coombs, C. C., … Mato, A. R. (2021). COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. Blood, 138(18), 1768–1773. https://doi.org/10.1182/blood.2021011841

Herrera, A., Cheng, A., Mimitou, E. P., Seffens, A., George, D., Bar-Natan, M., Heguy, A., Ruggles, K. V., Scher, J. U., Hymes, K., Latkowski, J.-A., Ødum, N., Kadin, M. E., Ouyang, Z., Geskin, L. J., Smibert, P., Buus, T. B., & Koralov, S. B. (2021). Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures. Blood, 138(16), 1456–1464. https://doi.org/10.1182/blood.2020009346